Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy - Pérol, Maurice; Ciuleanu, Tudor-Eliade; Arrieta, Oscar; Prabhash, Kumar; Syrigos, Konstantinos N.; Goksel, Tuncay; Park, Keunchil; Kowalyszyn, Ruben Dario; Pikiel, Joanna; Lewanski, Conrad R.; Thomas, Michael (Lung cancer, 2016)
Gesehen am 23.09.2020